Rhumbline Advisers Has $2.03 Million Stock Holdings in Apogee Therapeutics Inc. $APGE

Rhumbline Advisers lifted its position in Apogee Therapeutics Inc. (NASDAQ:APGE) by 3.2% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 54,385 shares of the company’s stock after acquiring an additional 1,665 shares during the quarter. Rhumbline Advisers owned approximately 0.12% of Apogee Therapeutics worth $2,032,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in APGE. Woodline Partners LP grew its position in Apogee Therapeutics by 4.5% during the first quarter. Woodline Partners LP now owns 1,061,053 shares of the company’s stock valued at $39,641,000 after buying an additional 45,445 shares during the period. Octagon Capital Advisors LP bought a new position in Apogee Therapeutics during the first quarter valued at about $399,752,000. Millennium Management LLC grew its position in Apogee Therapeutics by 100.0% during the first quarter. Millennium Management LLC now owns 260,335 shares of the company’s stock valued at $9,726,000 after buying an additional 130,164 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Apogee Therapeutics by 2.9% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,529 shares of the company’s stock worth $921,000 after purchasing an additional 694 shares during the period. Finally, Granahan Investment Management LLC boosted its position in Apogee Therapeutics by 16.7% during the first quarter. Granahan Investment Management LLC now owns 108,340 shares of the company’s stock worth $4,048,000 after purchasing an additional 15,486 shares during the period. Institutional investors own 79.04% of the company’s stock.

Insider Activity at Apogee Therapeutics

In related news, insider Carl Dambkowski sold 10,090 shares of Apogee Therapeutics stock in a transaction on Wednesday, July 2nd. The shares were sold at an average price of $45.09, for a total value of $454,958.10. Following the sale, the insider owned 238,998 shares in the company, valued at $10,776,419.82. The trade was a 4.05% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders have sold 15,540 shares of company stock valued at $661,104 over the last quarter. 42.77% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of brokerages have weighed in on APGE. BTIG Research increased their target price on shares of Apogee Therapeutics from $100.00 to $115.00 and gave the stock a “buy” rating in a research report on Monday, July 7th. Guggenheim reissued a “buy” rating and issued a $116.00 price target on shares of Apogee Therapeutics in a report on Wednesday, July 2nd. Citigroup reissued a “buy” rating on shares of Apogee Therapeutics in a report on Thursday, August 28th. Zacks Research downgraded shares of Apogee Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 14th. Finally, Wedbush reissued an “outperform” rating and issued a $90.00 price target on shares of Apogee Therapeutics in a report on Monday, August 11th. Seven equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $97.29.

Apogee Therapeutics Stock Performance

APGE stock opened at $37.63 on Thursday. The company has a market capitalization of $1.74 billion, a PE ratio of -9.11 and a beta of 1.42. Apogee Therapeutics Inc. has a one year low of $26.20 and a one year high of $63.50. The company’s 50 day moving average price is $37.74 and its two-hundred day moving average price is $38.02.

Apogee Therapeutics (NASDAQ:APGE) last posted its quarterly earnings results on Monday, August 11th. The company reported ($1.13) EPS for the quarter, missing the consensus estimate of ($1.03) by ($0.10). On average, research analysts predict that Apogee Therapeutics Inc. will post -3.09 EPS for the current year.

About Apogee Therapeutics

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.